請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38014
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賈景山(Jean-San Chia) | |
dc.contributor.author | Hui-Hsin Ko | en |
dc.contributor.author | 柯惠馨 | zh_TW |
dc.date.accessioned | 2021-06-13T15:56:36Z | - |
dc.date.available | 2011-08-13 | |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-06-10 | |
dc.identifier.citation | 1. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg. 2003;61:751-8.
2. Tralongo V, Rodolico V, Luciani A, Marra G, Daniele E. Prognostic factors in oral squamous cell carcinoma. A review of the literature. Anticancer Res. 1999;19:3503-10. 3. Herberman RB. The molecular basis of cancer. Cellular immunity. 1995;3:511-21. 4. Old LJ. Boyse EA. Immunology of experimental tumors. Annu Rev Med 1964;15:167-86. 5. Stutman O. Immunodepression and malignancy. Adv Cancer Res 1975;22:261-422. 6. Penn I. Malignant tumors in Organ transplant recipients. British J Surg 2005;59:161-2 7. Penn I. Posttransplant malignancies. Trasplant Proc 1999;31:1260-2. 8. Boshoff C., Weiss R. AIDS-related malignancies. Nature Rev Cancer 2002;2:373-82. 9. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L. Cancer risk after renal transplant in the Nordic countries. Int J Cancer 1995;60:183-9. 10. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical phase of primary cutaneous melanoma. Cancer 1996;77:1303-10. 11. Epstein NA, Fatti LP. Prognostic carcinoma: some morphological features affecting prognosis. Cancer 1976;37:2455-65. 12. Palma L., Di Lorenzo N., Guidetti B. Lymphocytic infiltrates in primary glioblastoma and recidivous gliomas. Incidence, fate and revalence to prognosis in 228 operated cases. J Neuosurg 1978;49:854-61. 13. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986;39:585-9. 14. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-9. 15. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. Tumor infiltrating lymphocytes as a independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1992;29:69-75. 16. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated whitin cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998:58:3491-4. 17. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G.. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. 18. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 1985;22:27-40. 19. Moy PM, Holmes EC, Golub SH. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 1985;45:57-60. 20. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict. Immunol Today 1997;18:493-7. 21. O'Mahony AM, O'Sullivan GC, O'Connell J, Cotter TG, Collins JK. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993;151:4847-56. 22. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993:60;247. 23. Sheu BC, Hsu SM, Ho HN, Lin RH, Huang SC. Tumor immunology- When a cancer cell meets the immune cells. J Formos Med Assoc 1999:98:730-5. 24. Gavin, M,Rudensky, A. Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr. Opin. Immunol. 2003;15:690-696. 25. Maloy, K.J, Powrie, F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001;2:816-822. 26. Piccirillo, C.A,Shevach, E.M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: Central players in the arena of peripheral tolerance. Semin. Immunol. 2004;16:81-88. 27. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001;182:18-32. 28. Jonuleit H, Schmitt E, Stassen M, Tuettenberg ., Knop J, Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001;193:1285-1294. 29. Atabani S.F, Thio C.L, Divanovic S, Trompette, A, Belkaid Y, Thomas D.L, Karp, C.L. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur. J. Immunol. 2005;35: 2157-2162. 30. Noma K, Yamaguchi Y, Okita R, Matsuura K, Toge T. The spleen plays an immunosuppressive role in patients with gastric cancer: Involvement of CD62L+ cells and TGF-beta. Anticancer Res. 2005;25: 643-649. 31. Chen ML, Pittet MJ, Gorelik L. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-b signals in vivo. Proc Natl Acad Sci USA 2005;102:419-24. 32. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-44. 33. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331-7. 34. Fontenot, J.D., Gavin, M.A., Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2005;4:330-336. 35. Turk, M.J., Wolchok, J.D., Guevara-Patino, J.A., Goldberg, S.M., and Houghton, A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 2002;188:122-135. 36. Nishikawa, H., T. Kato, I. Tawara, K. Saito, H. Ikeda, K. Kuribayashi, P. M. Allen, R. D. Schreiber, S. Sakaguchi, L. J. Old, H. Shiku. Definition of target antigens for naturally occurring CD4+CD25+ regulatory T cells. J. Exp. Med. 2005;201: 681-686. 37. Houghton, A. N., J. A. Guevara-Patino. Immune recognition of self in immunity against cancer. J. Clin. Invest. 2004;114: 468-471. 38. Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa, and C. J. Melief. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001;194: 823-832. 39. Tanaka, H., J. Tanaka, J. Kjaergaard, and S. Shu. Depletion of CD4 CD25 regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.J Immunother. 2002;25:207-217. 40. Antony, P. A., N. P. Restifo. Do CD4 CD25 immunoregulatory T cells hinder tumor immunotherapy? J. Immunother. 2002;25: 202-206. 41. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8. 42. Onizuka SI,Tawara J, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor amonoclonal antibody. Cancer Res1999;59:3128-33. 43. Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatoryT cells in wild-type hosts. Proc Natl Acad Sci US A 2005;102:9253-7. 44. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72. 45. Udaya K. Liyanage, Todd T. Moore, Hong-Gu Joo, Yoshiyuki Tanaka, Virginia Herrmann, Gerard Doherty, Jeffrey A. Drebin, Steven M. Strasberg, Timothy J. Eberlein, Peter S. Goedegebuure, David C. Linehan. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169: 2756-61. 46. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004 ;10: 942-949. 47. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12: 465-72. 48. Hiraoka N, Onozato K, KosugeT, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34. 49. Ormandy LA, Hillemann T,Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65: 2457-64. 50. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role ofT-regulatory cells. Hepatology 2005; 41:722-30. 51. Hua Zheng, Dian-Na Gu , Martin Braddock, Andrew J Leishman , Chang Jin MD, Jin-Sheng Wen , Yue-Wen Gong , Yong-Ping Chen . Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006;45: 254-62. 52. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12. 53. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.Cancer Res 2001;61:4766-72. 54. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1-2. 55. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164 56. Kuniyasu, Y., T. Takahashi, M. Itoh, J. Shimizu, G. Toda, S. Sakaguchi. Naturally anergic and suppressive CD25 CD4 T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 2000;12: 1145-1155 57. Kawaida, H., K. Kono, A. Takahashi, H. Sugai, K. Mimura, N. Miyagawa, H. Omata, A. Ooi, H. Fujii. Distribution of CD4 CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res. 2005;124: 151-157. 58. Schaefer, C., G. G. Kim, A. Albers, K. Hoermann, E. N. Myers, T. L. Whiteside. Characteristics of CD4 CD25 regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 2005;92: 913-920. 59. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54:369-377. 60. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55:1064-71. 61. Marc Beyer, Matthias Kochanek, Thomas Giese, Elmar Endl, Martin R. Weihrauch, Percy A. Knolle, Sabine Classen, Joachim L. Schultze. In vivo peripheral expansion of naive CD4 CD25high FoxP3 regulatory T cells in patients with multiple myeloma. BLOOD, 2006;107:3940-49 62. Ping Yu, Youjin Lee, Wenhua Liu, Thomas Krausz, Anita Chong, Hans Schreiber, Yang-Xin Fu. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91. 63. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915 64. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006;55:151–159 65. Kuniyasu, Y., T. Takahashi, M. Itoh, J. Shimizu, G. Toda, S. Sakaguchi. Naturally anergic and suppressive CD25 CD4 T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 2000;12: 1145-1155. 66. M Vitale, S Sivori, D Pende, R Augugliaro, C Di Donato, A Amoroso, M Malnati, C Bottino, L Moretta, A Moretta. Physical and functional independency of p70 and p58 cell receptors for HLA class I: Their role in the definition of different groups of alloreactive NK cell clones. Proc Natl Acad Sci USA 1996;93:1453-7. 67. Chien YH, Davis MM. How alpha beta T-cell receptors 'see' peptide MHC complexes. Immunol Today 1993;14:597-602. 68. Lanier LL. NK cell receptors. Ann Rev Immunol 1998;16:359-93. 69. M Vitale, S Sivori, D Pende, R Augugliaro, C Di Donato, A Amoroso, M Malnati, C Bottino, L Moretta, and A Moretta. p58 molecules as putative receptors for MHC class I molecules in human natural killer (NK) cells. Antip58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993;178:597-604. 70. Francisco Borrego, Matthias Ulbrecht, Elisabeth H. Weiss, John E. Coligan, Andrew G. Brooks. Recognition of human histocompatibility leukocyte antigen (HLA) –E complex with HLA class I signal sequence-derived peptide by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998;187:813-8. 71. Speiser DE, Pittet MJ, Valmori D, Dunbar R, Rimoldi D, Lienard D, MacDonald HR, Cerottini JC, Cerundolo V, Romero P. In vivo expression of natural killer-cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 1999;190:775-82. 72. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today. 1998b;19:153-7. 73. Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, Poggi A, Mingari MC, Moretta L. Major histocompatibility complex class I–specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997;155:105-17. 74. Alexander B., H. Bakker, Joseph H. Phillips, Carl G. Figdor,Lewis L. Lanier. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ T cells, and antigen-specific CTL. J Immunol 1998;160:5239-45. 75. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208. 76. Nadia Guerra, Maryvonne Guillard, Eric Angevin, Hamid Echchakir, Bernard Escudier, Alessandro Moretta, Salem Chouaib, Anne Caignard. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood 2000;95:2883-9. 77. Sardar T. A. K. Sindhu, Rasheed Ahmad, Richard Morisset, Ali Ahmad, and Jose Menezes. Peripheral blood cytotoxic gammadelta T lymphocytes from patients with human immunodeficiency virus type 1 infection and AIDS lyse uninfected CD4+ T cells, and their cytocidal potential correlates with viral load. J Virol 2003;77:1848-55. 78. J Kim, RL Modlin, RL Moy, SM Dubinett, T McHugh, BJ Nickoloff, K Uyemura . IL-10 production in cutaneous basal and squamous cell carcinomas- A mechanism for evading the local T cell immune response.J Immunol;1995:155:2240-7. 79. Stefania Bertone, Francesca Schiavetti, Rosa Bellomo, Chiara Vitale, Marco Ponte, Lorenzo Moretta, Maria C. Mingari. Transforming growth factor-β-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 1999;29:23-9. 80. Derre L, Corvaisier M, Pandolfino MC, et al. Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12:Implications for adoptive immunotherapy.J Immunol 2002;168:4864-70. 81. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53. 82. Ronchetti S, Zollo O, Bruscoll S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, Riccardi C GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004;34: 613-622 83. Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003;19:165-8. 84. O'Garra, A.,P. Vieira. Regulatory T cells and mechanisms of immune system control. Nat. Med. 2004;10: 801-805. 85. M. Strome, J.R. Clark, M.P. Fried, S. Rodliff and B.A. Blazar, T-cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck, Arch Otolaryngol Head Neck Surg.1987;113:1090-1093. 86. R.S. Selvan, M. Salvakumaran and A.R. Rao, Influence of arecoline on immune system: I. Short term effects on general parameters and on the adrenal and lymphoid organs, Immunopharmacol Immunotoxicol. 1989;11:347-377.v 87. Piccirillo, C. A.,A. M. Thornton. Cornerstone of peripheral tolerance: naturally occurring CD4 CD25 regulatory T cells. Trends Immunol. 2004;25: 374-380. 88. Ashley M. Miller, Kajsa Lundberg, Volkan Ozenci, Alison H. Banham, Magnus Hellstrom, Lars Egevad, Pavel Pisa. CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients.The Journal of Immunology 2006;177: 7398-7405 89. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8. 90. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200:771-82. 91. Viguier, M., F. Lemaitre, O. Verola, M.S. Cho, G. Gorochov, L. Dubertret, H. Bachelez, P. Kourilsky, L. Ferradini. Foxp3 expressing 7404 Tregs IN PC CD4 CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol.2004;173: 1444-1453. 92. Marshall, N. A., L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, M. A. Vickers. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103: 1755-1762. 93. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18: 423-449 94. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 2001;193: 1303-1310 95. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 2001;98: 2736-2744 96. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001;31: 1122-1131 97. Kuss I, Donnenberg A, Gooding W, Whiteside TL. Effector CD8+CD45RO CD27 T cells have signaling defects in patients with head and neck cancer. Br J Cancer 2003;88: 223–-230 98. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S, Annunziato F. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes.Blood 2003;102: 4107-4114 99. Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, Loser K, von Boehmer H, Buer J, Hansen W. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34: 623-630 100. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 2003;299:1057 101. Yong Peng, Hui Shao, Yan Ke, Ping Zhang, Gencheng Han, Henry J. Kaplan, Deming Sun. Minimally activated CD8 autoreactive T cells specific for IRBP express a high level of Foxp3 and are functionally suppressive. Invest OphthalmolVis Sci 2007;48:2178-84. 102. Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother 2007;30:294-302. 103. Strauss L,Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007;178: 320-9. 104. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, Levine SS, Fraenkel E, von Boehmer H, Young RA. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007;445: 831-5. 105. Laura Strauss, Christoph Bergmann,William Gooding, Jonas T. Johnson, Theresa L. Whiteside. The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 2007;21:6301-13 106. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo, AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer1 p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005;54:1072-1081. 107. Cao Y H-BS, Blum I, Bartels K, Faltz C, Leuwer R, Atanackovic D. A local enrichment of regulatory T cells within the tumor tissue might suppress an effective anti-tumor T cell response in patients with head and neck cancer. J Clin Oncol 2005;9666. 108. Chikamatsu K, Sakakura K, Whiteside TL, Furuya N. Relationships between regulatory T cells and CD81 effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 2007;29:120-127. 109. Amarnath S PV, Gutkind SJ, Chen W. Human oral cancer cells induce CD41CD251FOXP31 regulatory cells from CD41CD252 T cells through production of TGFb. In: American Association of Immunologists, late breaking abstracts, Boston, MA, 2006 110. Lars A. Ormandy, Tina Hillemann, Heiner Wedemeyer, Michael P. Manns, Tim F. Greten, and Firouzeh Korangy. Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Res 2005; 65:2457-2464 111. Noritoshi Kobayashi, Nobuyoshi Hiraoka, WataruYamagami, Hidenori Ojima, Yae Kanai, Tomoo Kosuge, Atsushi Nakajima,3 Setsuo Hirohashi. FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis. Clin Cancer Res 2007;13: 902-911 112. Edward Y. Woo, Christina S. Chu, Theresa J. Goletz, Katia Schlienger, Heidi Yeh, George Coukos, Stephen C. Rubin, Larry R. Kaiser, Carl H. June. Regulatory CD41CD251 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer. Cancer Res 200;61: 4766-72. 113. Abdeljabar El Andaloussi, Maciej S. Lesniak. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumorinfiltrating lymphocytes of human glioblastoma multiforme. Neuro-Oncology 2006;8:234-243. 114. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467-1473. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38014 | - |
dc.description.abstract | 在口腔中約90%的惡性腫瘤為口腔鱗狀細胞癌,而在台灣是一個前六大男性常見侵襲癌症死因,此外台灣主要是和嚼食檳榔、五年的存活率不佳以及高度死亡率著稱。在頭頸部腫瘤中,許多腫瘤產生之免疫抑制性機轉被提出,但是否在口腔鱗狀細胞癌中有類似的現象仍不清楚。在本篇研究中,針對治療前後,CD4+CD25+ 調節性T細胞在周邊血液的分布調、CD8+T淋巴球中自然殺手細胞抑制受體 (inhibitory natural killer cell receptors,iNKRs),以及其他不同種類T淋巴球的表現。實驗中,我們針對30個口腔鱗狀細胞癌的病患 (其TNM分期為第一至四期) 以及20個年齡相符的健康正常血液捐贈者取其血液中之單核球利用單株抗體和三或四色之流式細胞儀進行分析。我們發現在口腔鱗狀細胞癌病患之周邊血液中,比正常對照組有較高之CD4+/CD8+比例,而主要是由於 CD8+ T cells下降的關係;而在深入分析CD3+CD4+之淋巴球中CD25+ 之調節性T淋巴球在口腔鱗狀細胞癌病患(5.86±5.23%)之週邊血液相對於正常捐贈組(1.68±0.95%)有統計學上意義(p<0.001);再者,將上述明顯表現的CD4+CD25+調節性T淋巴球藉由流式細胞儀再依據細胞的分布來進一步分析細胞的表現,CD4+ CD25+高度表現群在口腔鱗狀上皮細胞癌病患(1.84±1.74%) 週邊血液相較於正常捐贈組(0.43±0.40%)是具有統計學上意義的(p<0.005);更者,我們以細胞內染色來標定Foxp3,利用它為一重要之轉錄因子以及為調節性T細胞之專一分子標定記號來做進一步確認CD4+ CD25+高度表現群與低度表現群為調節性T淋巴球。而我們也發現CD4+ CD25+高度表現群和TNM分期和癌症發生之位置並無明顯相關。在病患接受治療後,在口腔鱗狀細胞癌中CD4+ CD25+之比例也較術前減少 (2.87±2.69 %, p<0.05)。然而在CD8+ T淋巴球中自然殺手細胞抑制受體,無論是NKG2A或NKG2D和正常對照組並無明顯差異。但在CD4+/CD8+比例以及治療前發現減少之CD8+數量在接受治療後皆有發現逐步恢復正常的情況。這些結果顯示在循循環血液中之調節性T細胞和疾病之嚴重度以及CD8+數量之下降量有直接的關係。而調節性T細胞對癌症病患體中所造成之效應可以幫助我們未來在口腔鱗狀細胞癌治療之方向。 | zh_TW |
dc.description.abstract | Oral squamous cell carcinoma (OSCC) accounts for more than 95% of all malignant neoplasms in the oral cavity, and ranks as the sixth major cause of cancer mortality in Taiwan. Here, OSCC is associated with the areca nut chewing and characterized by an unsatisfactory 5-year survival rate after treatment. Emerging evidence suggested that head and neck carcinoma exhibits multiple immunosuppressive characteristics, but whether OSCC displays similar phenomenon is still not clear. In the present study, the distribution of CD4+CD25+ regulatory T cells (Treg) in the peripheral blood before or after treatment and the change in ratio or iNKR markers of CD8+T lymphocytes were investigated. we also examined the expression of various on T lymphocytes (especially). A total of 30 OSCC patients (TNM Stage I to IV) and 20 aged-match healthy donors were enrolled and their peripheral blood mononuclear cells (PBMCs) were analyzed by triple-color and quadruple
flow cytometry using a panel of specific monoclonal antibodies. Patients with OSCC had significantly higher CD4+/CD8+ ratio than normal controls attributable to a decrease in CD8+ T cells. Among the CD3+CD4+ subsets, CD25+ Treg represented 5.86±5.23 % in OSCC patients or 1.68±0.95 % in normal controls (p < 0.001). Furthermore, Mean percentage of CD4+CD25high Treg, which exhibited higher mean flurescence intensity of CD25+ expression, of OSCC patients (1.84±1.74%) is also significantly higher than in healthy donors (0.43±0.40 %, p< 0.005). Identity of Treg in both CD4+CD25high or CD4+CD25low subsets were confirmed by a positive intra-cellular staining of Foxp3+, an important transcription factor and the most specific molecular marker for regulatory T cells. The increase in CD25high Treg was related to TNM stage, but not site of cancer occurrence. After treatment, the percentage of CD4+CD25+ Treg in the OSCC patients decreased significantly (2.87±2.69 %, p<0.05) to the level comparable to (before) normal controls. There was no significant difference in the expression of iNKRs, NKG2A or NKG2D, on circulating CD8+ T cells from OSCC patients compared to normal controls. But the increased CD4+/CD8+ ratio or the decreased CD8 number in OSCC patients converted to normal level after treatment. These results suggested that the frequency of circulating Treg correlated directly with the severity of disease and the decreased circulating CD8+ count in OSCC patients, and conversion of circulating Treg might reflect efficacy of cancer treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:56:36Z (GMT). No. of bitstreams: 1 ntu-97-R95422008-1.pdf: 1585569 bytes, checksum: fe59c0442261cc745e2deda4f9da25f2 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 目錄 ………………………………………………………………I
圖表目錄……………………………………………………………II 中文摘要……………………………………………………………1 英文摘要……………………………………………………………2 第一章 研究背景……………………………………………………3 第一節 口腔癌的發生率………………………………………3 第二節 免疫監督 ………………………………………………4 第三節 免疫逃避性……………………………………………4 第四節 調節性T細胞………………………………………………5 第五節 調節性T細胞與癌症之關係....6 第六節 調節性T細胞與頭頸部癌症之關係...7 第七節 自然殺手細胞抑制受體…………………………………8 第二章 研究目的與假說 ………………………………………………10 第三章 材料與方法 …………………………………………………11 第一節 病例收集………………………………………………11 第二節 周邊血液收集………………………11 第三節 細胞免疫染色……………………………………11 第四節 流式細胞儀分析............12 第五節 表現比例的定義…….12 第六節 統計結果分析......12 第四章 結果………………………………………………………….14 第一節 分析CD3+之T 細胞之次族群表現....14 1-1、口腔鱗狀上皮細胞癌組織及周邊血液與正常對照組分離出的細胞..14 1-2、口腔鱗狀上皮細胞癌病患的週邊血液與正常對照組之比較..14 1-3、周邊血液在口腔鱗狀上皮細胞癌病患與正常對照組之調節T 細胞表現量..14 1-4、口腔鱗狀上皮細胞癌病患的週邊血液單核細胞球之CD8+ T 淋巴球CD94與NKG2A表現..14 第二節 分析CD4+CD25+ 調節性T 細胞之次族群表現..15 2-1、CD4+CD25high T 細胞在口腔鱗狀上皮細胞癌之週邊血液的表現量..15 2-2、在 CD4+CD25+ 調節性T細胞上Foxp3 之表現..15 2-3、CD4+CD25+ 調節性T細胞的表現型分析..16 2-4、治療後之病患之 CD4+CD25+ 調節性T細胞改變量..16 第五章 討論………………………………………………………….17 第六章 結論...21 參考文獻………………………………………………………………22 附圖……………………………………………………………………29 附表……………………………………………………………………36 附件……………………………………………………………………41 | |
dc.language.iso | zh-TW | |
dc.title | 口腔鱗狀細胞癌病患週邊血液中調節性T細胞的變化 | zh_TW |
dc.title | change in frequency of Regulatory T cells in peripheral blood from Patients with Oral Squamous Cell Carcinomas | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 郭生興(Sang-Heng Kok),許博欽(Bor-Ching Sheu) | |
dc.subject.keyword | 口腔鱗狀細胞癌,周邊血液單核球細胞,調節性T淋巴球, | zh_TW |
dc.subject.keyword | OSCC,PBMC,Regulatory T cell, | en |
dc.relation.page | 47 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-06-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 1.55 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。